ACST Acasti Pharma Inc.

0.66
-0.01  -2%
Previous Close 0.67
Open 0.68
Price To Book 13.67
Market Cap 51564854
Shares 78,128,567
Volume 455,192
Short Ratio
Av. Daily Volume 1,162,005

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due by the end of 2019.
CaPre (TRILOGY trial)
Hypertriglyceridemia

Latest News

  1. Acasti Pharma to Present at the 11th Annual LD Micro Main Event
  2. Acasti: Fiscal 2Q Earnings Snapshot
  3. Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
  4. Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
  5. Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option
  6. Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
  7. Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review
  8. Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares
  9. The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut
  10. Acasti Pharma Announces Public Equity Offering
  11. Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares
  12. The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares
  13. Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
  14. Today’s Research Reports on Stocks to Watch: Achieve Life Sciences and Acasti Pharma
  15. Acasti Pharma Appoints Jean-François Boily as Vice President of Finance
  16. Acasti Pharma Provides Clinical and Market Update
  17. Acasti: 2Q Earnings Snapshot